Hope for 5.1 million American’s who suffer from Heart Failure.

 

This biotechnology company has pioneered a treatment that strengthens cardiac muscle contraction by employing a derivative of the essential human energetic unit known as Adenosine Triphosphate (ATP).

 

ATP is the fundamental source of energy in the human body. The company has discovered a means to direct this energy source to repair the heart through a novel biological agent that raises the production of DeoxyAdenosine Triphosphate (dATP) in the metabolic synthesis of ATP.

 

Since dATP lacks one hydroxyl group that ATP has and is a smaller compound, it diffuses faster through the cellular gap junctions and in turn, there is a more rapid release of myosin and a faster relaxation stroke of the heart muscle. The result is a super fuel for the heart increasing the hearts power to pump blood.

 

The result is an increase in the dATP-to-ATP ratio that simultaneously improves heart contraction and muscle relaxation. Each heartbeat is stronger and more effective.

 

For the millions of people suffer from heart failure, this technology can change their lives. Most of those afflicted have extremely limited lives and about half will die within 5 years. Heart failure accounts for 20% of US healthcare costs.

 

Common medical treatments offer little benefit. Despite the widespread use of these varying options, 25% of those living with some heart failure condition die within the first year, and only 50% survive more than 5 years.

 

As a result the National Institute of Health has invested over $50 million to develop this technology. 

 

Unlike most biotechnology innovations that require clinical trials that require years and tens of millions, these trials will have results within weeks. The FDA has been supportive of gene therapy and given the dearth of alternatives the FDA is very supportive. 

 

The company is ready to start trials. The risk now is execution. This is reduced by world class team that has assembled around this technology.  Run by a former venture capitalist, they have chosen to seek capital from individual investors. 

 

UPSIDE OPPORTUNITY

It has obtained exclusive, worldwide rights to a strong IP portfolio and envisions a sizable share of the projected $20 B market in 2016.

 

FINANCING

The client has successfully raised $3 MM in angel round and plans to raise an additional $20 MM in Series A. The A round can be broken into 2 tranches of $8 MM and $12 MM to get through human clinical trials.

 

OF NOTE

Early pre–clinical results have shown marked improvements in cell contraction in rats. The experimental data indicates that an increase in dATP from 0.1 % to 2 % has a significant effect on contractility. In addition, computer modeling results show a strong interaction between a protein residue and dATP in the myosin binding pocket. 

 

CLICK HERE FOR THE CEO INTERVIEW